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Abstract 
Background: Major depressive disorder (MDD) is a common psychiatric disorder with considerable mortality. 
Death from unnatural causes, largely suicidal or quasi-suicidal, has a particularly high risk for the functional disorders, 
especially depression and schizophrenia. One of the prospective risk factors for this disease is hyperhomocysteinemia 
and folate deficiency. The methylenetetrahydrofolate reductase (MTHFR) gene encodes for a 5-methylenetetrahydro-
folate reductase involved in folate metabolism and neurotransmitter synthesis. The aim of this research is to study the 
association between the C677T polymorphism of MTHFR gene and depression in Tunisian population, to explore their 
relationship with clinical and therapeutic characteristics of this disease. And it may lead to discover a novel marker to 
identify a patient with a higher risk of development of depressive disorder to be. This marker can be used for better 
therapeutic management and prevent disease installation.
Methods: Our study included 208 depressive patients, 187 controls aged between 44.1 ± 13.5 and 38.9 ± 13.2 years, 
respectively. MTHFR gene polymorphisms were determined by PCR–RFLP (polymerase chain reaction–restriction frag-
ment length polymorphism).
Results: No significant difference was detected in the distribution of the genotype frequencies of MTHFR C677T 
polymorphisms (χ2 = 5.443, df = 2, p = 0.066) between patients and controls. But when we study the risk of these 
genotypes, CT genotype is significantly more frequent in controls compared to patients, it may be a protection from 
depression (OR = 0.655, CI 95 % = 0.432–0.995, p = 0.047, OR* = 0.638, CI 95 %* = 0.415–0.983, p* = 0.04, before and 
after adjustment). Women, TT Genotype can increase four times the risk to be depressive. Addictive behavior seems to 
be associated with CT genotype and there was no significant association between clinical and therapeutic character-
istics and this polymorphism.
Conclusion: This paper is the first study to prove that CT genotype of MTHFR C677T polymorphism may protect 
from depression and TT genotype seems to be associated with women’s depression. Further studies are required with 
other polymorphisms and biochemical factors that must be investigated to clarify the implication of MTHFR C677T 
polymorphism in the pathophysiology of depression.
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Background
Major depressive disorder (MDD) is a common psychiat-
ric disorder with considerable mortality [1] which affects 
121 million people worldwide [2]. The prevalence of 
depression in Tunisia is over 7 % [3]. Death from unnatu-
ral causes, largely suicidal or quasi-suicidal, has a particu-
larly, high risk for substance abuse and eating disorders 
and a high risk for the functional disorders, especially 
MDD and schizophrenia [1]. The etiology of this MDD 
remains unclear, both gene–gene and gene-environment 
interactions are believed to have an important role on the 
development of this disease [4].
The genetic of depression has been extensively inves-
tigated, López-León et  al. [5] has listed more than 393 
polymorphisms in 102 genes, who were tested to have 
a possible relationship with depression. One promis-
ing candidate genetic marker for depression prognosis 
is the methylenetetrahydrofolate reductase (MTHFR) 
gene. This gene encodes for a 5-methylenetetrahydro-
folate reductase involved in folate metabolism and 
neurotransmitter synthesis. Folate, vitamin B6 and vita-
min B12 are used as cofactors in the metabolisation of 
homocysteine. Hyperhomocysteinemia and folate defi-
ciency are prospective risk factors for depression [6–9]. 
Homocysteine or its metabolites may have an excitotoxic 
effect on neurons and may inhibit methylation processes 
in the central nervous system, it is toxic to the neurons, 
endothelial cells, can induce DNA strand breakage, oxi-
dative stress, and apoptosis [10, 11]. This reduction of 
the MTHFR enzyme activity and the mild elevation of 
homocysteine plasma are probably caused by the C-T 
substitution at the 677 nucleotide in the MTHFR gene 
and it seems to be the major genetic cause [12]. Studies 
are focused on this hypothesis but controversial results 
are found in the case–control studies investigating the 
association between the MTHFR C677T polymorphism 
and depression. Gilbody et al. [7] and Wu et al. [13], in 
their meta-analysis have found a positive association 
with MTHFR C766T polymorphism and the risk of 
depression, but Zintzaras [14] and Gaysina et  al. [15] 
reports the absence of association in their meta-analysis. 
These controversial results may be explained by the size 
of population and the ethnic and geographic variation 
between populations.
In our case, we searched to study the relationship of 
this polymorphism with depression and different charac-
teristics (socio-demographic, clinical and therapeutics) in 
Tunisian population of center. And this may lead to dis-
cover a novel marker to identify a patient with a higher 
risk of development of depressive disorder. This genetic 
marker can be used for better therapeutic management 
and prevent disease installation through treatment, psy-
chological support and nutrition. A detection particular 
combination of polymorphism of different genes may 
confer a better exploration of earlier onset or presence of 
the different forms of pathology.
Patients and methods
Study population
The study was conducted in the Department of Psy-
chiatry, of the University Hospital of Monastir, Tunisia, 
included 208 depressive patients and 187 controls with-
out psychiatric or somatic pathology. The mean age of 
the 208 patients, including 91 males and 117 females, 
was 44.11  ±  13.52  years, while the mean age of the 
187 controls including 91 males and 95 females, was 
38.53 ± 13.22 years.
This study was approved by the local ethical committee 
and all subjects were of Tunisian origin. It is interesting 
to note that the Tunisian population is essentially Arabs, 
Berbers or most of the time, mixed between those two 
ethnical origins [16]. Consensus on the diagnosis, accord-
ing to the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition (DSM-IV) criteria (American 
Psychiatric Association, 2004), was made by psychiatrists. 
The exclusion criteria were age below 18 years, other psy-
chiatric illnesses, epilepsy or mental retardation. All sub-
jects were questioned about their age, gender, previous 
treatments, cigarette and alcohol consumption habits. All 
Controls filled out the same questionnaire and confirmed 
to be not depressed by the Beck Depression Inventory 
(BDI). The clinical and socio-demographic characteristics 
are shown in Table 1.
Genotype analysis
Genomic DNA was extracted and isolated from EDTA 
blood samples by salting-out method [17]. The MTHFR 
C677T polymorphisms of the 5,10-methylenetetrahydro-
folate reductase gene has been studied by the protocol 
described previously by Frost et al. [18]. In brief, a poly-
merase chain reaction (PCR) method using specific prim-
ers was carried out and the PCR products were digested 
with HinfI and then electrophoresed on 3 % agarose gels 
stained with ethidium bromide and UV transillumina-
tion. The uncut amplicon is 198 base pairs (bp) length. 
After digestion, the “T” allele gives 173 and 25  bp frag-
ments, and the “C” allele gives one fragment with 198 bp 
fragments.
Statistical analysis
We have performed a case–control study on depressive 
and safe Tunisian population. Statistical analyses were 
performed using SPSS 17.0 (SPSS, Chicago, IL, USA). 
Hardy–Weinberg equilibrium was evaluated and geno-
type frequencies were compared by Chi-squared test 
(χ2). Quantitative variables were presented as mean ± SD 
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and comparisons were performed using the Student’s t 
test. Qualitative variable comparisons were performed 
using the χ2 test. Odd ratios (ORs) and their 95  % con-
fidence interval (CI) were calculated. The differences in 
demographic, clinical and therapeutic characteristics 
of patients were assessed among the MTHFR genotype 
using analysis of variance (ANOVA). Adjustment for 
potential confounder factors (age, drugs consumption) 
was performed by binary logistic regression. The statisti-
cal significance level was set at p ≤ 0.05.
Results
In our population, depression is highly associated 
with age (p  <  0.001) and specifically with old persons 
(≤50  years) with p =  0.021, but no difference has been 
associated with the other demographic characteristics 
of our population (Table  1). Moreover, no significant 
difference was detected in the genotype frequencies 
(χ2 = 5.443, df = 2, p = 0.066) between patients and con-
trols (Table 2).
On the other side, study of risk demonstrated that CT 
genotype was more frequent in controls then depres-
sives (51 vs 43  %, respectively), with significant asso-
ciation (OR = 0.655, CI 95 % = 0.432–0.995, p = 0.047, 
OR* = 0.638, CI 95 %* = 0.415–0.983, p* = 0.041 before 
and after adjustment to confound factors) (Table  3). 
However, TT genotype was more prevalent in depres-
sive (11 %) compared to controls (7 %), but not significant 
(p = 0.544 and p* = 0.698 before and after adjustment) 
(Table  3). When we focused on gender, we have found 
a positive association between TT genotype and the 
pathology in Women (OR  =  4.161, CI 95  %  =  0.886–
19.540, p  =  0.053, OR*  =  0.4.233, CI 95  %*  =  0.834–
21.391, p* = 0.082), but no association was found for men 
(Tables 4, 5, 6, 7).
In addictive behavior, CT genotype was present fre-
quently in our depressive population. 61.9  % of alcohol 
consumers have the CT genotype, compared to no con-
sumers who have just 35.6  % with (p  =  0.001). In the 
other side, the CT genotype was present in 70.6  % of 
the depressive consumers of drugs of abuse (p = 0.013) 
(Table 8). We also found that 50 % of smokers have the 
CT genotype (p = 0.058).
For those who have suicide attempts history, 17.9  % 
of them have the TT genotype, and 50 % have CT gen-
otype (p =  0.099) (Table  8). Moreover, we noticed that 
CC genotype is more frequent then CT and TT geno-
types in patients who have atypical depression (55.6  %) 
with medium severity (71.4  %) which associated to 
anxiety (54.1  %) specially panic one (67.7  %). In addi-
tion, we found that CC genotype is also more frequent 
with patients who have depression Cluster C (Table  8). 
Depressive patients, who have CT genotype, are fre-
quently treated by Mixed Antidepressant (selective inhib-
itors of serotonin reuptake, tricyclic antidepressant) and 
usually use sertraline (Table 8).
Discussion
To our knowledge, no study was done in Tunisian 
depressed population related to the C677T polymor-
phism. A significant association was found between age 
and pathology, The patients have the highest mean age 
with 44.11  ±  13.52  years, and the pathology is associ-
ated with the oldest cohort of our population (>50 years) 
Table 1 Demographic and clinical data of the study popu-
lation
Patients Controls p
Gender: male/female (ratio) 91/117 91/96 0.328
Age (years) 44.11 ± 13.518 38.53 ± 13.222 <0.001
Age group
 Youth (<20 years) 11 (5.3 %) 17 (9 %) 0.021
 Adult (20 ≤ years < 50) 122 (58.6 %) 125 (66.9 %)
 Old (≤50 years) 75 (36.1 %) 45 (24.1 %)
BMI (kg/m2) 27.098 ± 5.60 26.962 ± 4.58 0.793
Obesity
 Normal 72 (34.6 %) 71 (38 %) 0.361
 Over weight 75 (36.1 %) 73 (39 %)
 Obese 61 (29.3 %) 43 (23 %)
Cigarette smoking 0.93
 Smokers 64 (32 %) 59 (32 %)
 Non-smokers 136 (68 %) 128 (68 %)
Alcoholic beverages 0.807
 Consumers 42 (20.2 %) 40 (21.4 %)
 Non-consumers 164 (78.8 %) 147 (78.6)
Drugs use
 Yes 17 (8.2 %) 8 (4.3 %) 0.112
 No 191 (91.8 %) 179 (95.7 %)
Treatments
 No 26 – –
 Tricyclic antidepressants 
(TCA)
42 –
 SIRS 94 –
 Atypique 16 –
 SIRS + TCA 6 –
Table 2 Genotype frequencies of  the C677T polymor-
phisms in the gene in patients and in controls
Genotype Patients Controls χ2, df, p
CC 105 (51 %) 80 (43 %) χ2 = 5.443/ddl = 2//p = 0.066
CT 80 (38 %) 93 (50 %)
TT 23 (11 %) 14 (7 %)
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with p = 0.021. Elderly person have many difficulties with 
activities of daily living, and many studies demonstrated 
that this difficulties are associated with increase of 
depressive symptoms increased with age [19]. Our result 
can be explained also by the higher levels of homocyst-
eine usually in depressed subjects compared to controls. 
The plasma level of homocysteine is influenced by factors 
such as age, so it is possible that such effects contribute 
to the cascade of events leading to depression in later life 
[20].
We have not found any association between MTHFR 
polymorphism and unipolar depression, this result is 
similar to the findings of Kunugi et  al. [21] and Hen-
riquez-Hernandez et  al. [22]. In a cohort of 277 Slovak 
with 143 controls subjects and 134 depressed patients, 
Evinova et al. [4] did not find any significant association 
with this polymorphism and major depressive disorders. 
On the other hand, meta-analysis of 26 studies, conclude 
that the MTHFR C677T is associated with increased risk 
of depression [13]. Reif et al. [23], have found a positive 
association between the same MTHFR polymorphism 
and Major depressive disorder.
In our study, CT genotype was more frequent and sig-
nificantly in controls than depressives and after adjust-
ment, this association remained significant. So CT 
genotype may be protecting from depression. This result 
is annoyed by the work of Shen et al. [24], who examined 
368 patients and 219 controls, and he found a positive 
association between the CT genotype (p  <  0.001) and 
depression.
Arinami et al. [25] have been the first ones who focused 
on this gene polymorphism, and found that TT genotype 
has a higher prevalence with depression with 2.8 as odd 
ratio. The same result was found in the meta-analysis of 
17 articles by Peerbooms et  al. [26] suggesting that TT 
genotype increase risk of receiving the diagnosis of major 
depressive disorders.
On the other hand, Bjelland et  al. [6], report a posi-
tive association between TT genotype and higher level of 
homocysteine with depression without comorbid anxiety 
disorder. In Slovak population, TT genotype of C677T 
and AC genotype of A1298C of BDNF gene are consider-
ably associated with the higher risk of major depression 
disorders [4].
In Poland population, Chojnicka et  al. [27], have not 
found any association between the polymorphism and 
completed suicide, the same result is found in our study. 
A lake of association is supported by several studies [21, 
23, 28–31]. The same contradictory results are shown in 
meta-analysis, Gilbody et  al. [7], Lok et  al. [32], López-
León et al. [5] and Wu et al. [13] indicate that TT geno-
type increase the risk of depression disorders but Gaysina 
Table 3 Association between depression and MTHFR C766T polymorphisms
OR IC 95 % p ORa IC 95 % adjusted p
N(CC) 1 – –
H(CT) 0.655 0.432–0.995 0.047 0.638 0.415–0.983 0.041
M(TT) 1.252 0.606–2.585 0.544 1.161 0.546–2.469 0.698
Table 4 Genotype frequencies of  the C677T polymor-
phisms in the gene in men patients and in men controls
Patient Controls Total
MTHFR1
 N(CC) 43 37 80 χ2 = 0.810/ddl = 2//p = 0.667
 H(CT) 37 42 79
 M(TT) 11 12 23
Total 91 91
Table 5 Association between depression and MTHFR C766T polymorphisms in men
OR IC 95 % p ORa IC 95 % adjusted p
N(CC) 1 – – – – –
H(CT) 0.758 0.406–1.414 0.383 0.645 0.333–1.250 0.194
M(TT) 0.789 0.312–1.997 0.616 0.755 0.295–1.933 0.558
Table 6 Genotype frequencies of  the C677T polymor-




 N(CC) 62 43 105 χ2 = 8.921/ddl = 2//p = 0.012
 H(CT) 43 50 93
 M(TT) 12 2 14
Total 117 95 212
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et al. [15] and Zintzaras [14], confirmed a lake of signifi-
cation between the polymorphism and the pathology.
These controversial results may be due to the small 
sample sizes or to the influence of ethnic and demo-
graphic differences. Wu et  al. [13] found that MTHFR 
C677T polymorphism is correlated to depression of 
Asian population in all genotype models, but only a mar-
ginal correlation was observed among white populations 
in recessive model. He showed that Asian population had 
a greater genetic risk to develop depression in compari-
son with white population. This also can be explained by 
the nature of food which is fortified with folate, so the TT 
effect cannot be observed [33].
According to gender, no association was found in men 
between depression and C677T, but in women, we found 
a positive association (χ2  =  8.921, df  =  2, p  =  0.012) 
and that TT genotype increase the risk of developing 
depression by four times referring to CC genotype with 
(p = 0.053 and p* = 0.082 before and after adjustment). 
These results show a greater genetic risk in women to 
develop depression.
Słopien et al. [34] found a higher correlation with TT 
genotype and depression found in post menopausal 
women (OR = 3.478; 95 % CI = 1.377–8.783; p = 0.0096), 
and this genotype displayed about 4.8-fold increased risk 
of moderate and severe depression (CI 95  %  =  1.975–
11.820, p  =  0.0008). This association is confirmed by 
the work of Lewis et  al. [35] on British Women’s Heart 
and Health Study with 545 women (OR  =  1.35, 95  % 
CI = 1.1–1.8). It’s not supported by Kempisty et al. [36] 
who found a higher percentage of T allele in men com-
pared to women and suggest that the 667T allele might 
represent a minor liability in women or an increased sur-
vival advantage for men.
No association is found in the work of Gaysina et  al. 
[15] between depressive women and C677T polymor-
phism with (χ2 = 2 1.5; ddl = 2; p = 0.47) but Almeida 
et al. [37] did not find association in older women. Focus-
ing on demographic characters, we find that CT geno-
type seems to be associated with addictive behavior in 
depressed people [37].
In our population, the major frequency of alcohol 
consumers, drugs abuse and smokers has a CT geno-
type who has been demonstrated previously as a protec-
tor from depression. We can explain this result by the 
neutralization of the protective effect of the CT geno-
type by the addictive behavior and the gene environment 
interaction. Patients need a good lifestyle to be protected, 
without addictive behavior that can change the gene 
effect.
Otherwise these associations can be explained by 
the relation between the levels of homocysteinemia 
and C677T genotype. Hultberg [38] demonstrated that 
chronic alcoholism was associated with hyperhomocyst-
einemia. On the other side Benyamina et al. [39] suggest 
that MTHFR 677TT genotype could play a protective 
role against alcohol dependence.
Lok [40] suggest that the interaction between 
MTHFR C677T and cannabis increased risk of recur-
rence in recurrent major depressive disorder patients 
over 5.5  years of follow-up and is associated with 
depressive symptoms in the general population. The 
study of Guillem et al. [41] confirms the high mood and 
anxiety disorders comorbidity among dependent users 
of cannabis. Also there are also studies that is show-
ing low folate level due to cannabis abuse in pregnant 
women [42] and undergraduate students [43]. Canna-
bis abuse is associated with higher Homocysteine, as 
well as lower HDL and vitamin B12 levels first-episode 
schizophrenia [44].
Smoking is also associated with depression, and smok-
ing is known to be associated with higher homocysteine 
plasma levels [45]. Moreover, Brown [46] confirms that 
the T allele and smoking interact in their association with 
homocysteine plasma levels. The T allele in smoking group 
had the highest level of homocysteine, in the opposite of C 
allele who had the lowest levels of homocysteine plasma.
Variant alleles (CT, TT) have been linked with 
increased serum homocysteine concentrations [47, 48], 
so this association can be explained by the gene environ-
ment influence on homocysteine level and cause depres-
sion, and we think that drugs, alcohol and smoking intake 
interfere with folate metabolism and affect the level of 
homocysteinemia.
No significant association was found between 
rs1801133 (C677T) polymorphism and suicide behav-
ior (p = 0.682), suicide ideation (p = 0.603) and suicide 
attempts (p =  0.629) [49]. In Polish Caucasians popula-
tion, MTHFR C677T polymorphism is admitted like not 
a risk factor for completed suicide with TT [27].
Table 7 Association between depression and MTHFR C766T polymorphism in women
OR IC 95 % p ORa IC 95 % adjusted p
N(CC) 1 – – – – –
H(CT) 0.596 0.340–1.048 0.071 0.613 0.342–1.099 0.100
M(TT) 4.161 0.886–19.540 0.053 4.233 0.834–21.391 0.082
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Age 45.37 ± 13.036 42.16 ± 14.132 45.09 ± 13.287 0.261
BMI 27.127 ± 5.992 26.8113 ± 5.992 27.965 ± 5.201 0.685
Gender
 Man 43 (47.2 %) 37 (40.7 %) 11 (12.1 %) 0.707
 Women 62 (53 %) 43 (36.8 %) 12 (10.2 %)
Alcohol
 Yes 12 (28.6 %) 26 (61.9 %) 4 (9.5 %) 0.001
 No 19 (11.6) 52 (31.7 %) 93 (56.7 %)
Drugs
 Yes 5 (29.4 %) 12 (70.6 %) (0 %)0 0.013
 No 100 (52.4 %) 68 (35.6 %) 23 (12 %)
Smoker
 Yes 28 (41.2 %) 34 (50 %) 6 (8.8 %) 0.058
 No 77 (55 %) 46 (32.9 %) 17 (12.1 %)
Suicide attempts
 Yes 9 (32.1 %) 14 (50 %) 5 (17.9 %) 0.099
 No 96 (53.3 %) 66 (36.7) 18 (10 %)
Characteristics
 Psychotic 19 (45.2 %) 16 (38.1 %) 7 (16.7 %) 0.705
 Melancholic 71 (51.1 %) 55 (39.6 %) 13 (9.3 %)
 Atypical 15 (55.6 %) 9 (33.3 %) 3 (11.1 %)
Severity 2
 Low 12 (36.4 %) 14 (42.4 %) 7 (21.2 %) 0.052
 Medium 75 (55.1 %) 52 (38.2 %) 9 (6.7 %)
 Severe 18 (46.2 %) 14 (35.9 %) 7 (17.9 %)
Anxiety associated
 Yes 60 (54.1) 39 (35.1) 12 (10.8) 0.522
 No 45 (46.4) 41 (42.3) 11 (11.3)
Type of anxiety
 Panic 23 (67.7 %) 10 (29.4) 1 (2.9 %) 0.129
 General anxiety 37 (48.1 %) 30 (38.9 %) 10 (13 %)
 Obsessive compulsive 4 (100 %) 0 0
 Panic and general anxiety 0 1 (100 %) 0
Personality disorders
 No 39 (50 %) 32 (41.1 %) 7 (8.9 %) 0.702
 Yes 66 (50.8 %) 48 (36.9 %) 16 (12.3 %)
Cluster
 Cluster A 1 (25 %) 2 (50 %) 1 (25 %) 0.818
 Cluster B 18 (48.7 %) 15 (40.5 %) 4 (10.8 %)
 Cluster C 10 (55.6 %) 6 (33.3) 2 (11.1 %)
Adaptation
 No 27 (54 %) 19 (38 %) 4 (8 %) 0.662
 Almost 44 (45.4 %) 40 (41.2 %) 13 (13.4 %)
 Better 34 (55.8 %) 21 (34.4 %) 6 (9.8 %)
Treatment
 No 28 (54.9 %) 18 (35.3 %) 5 (9.8 %) 0.806
 TCA 19 (45.2 %) 16 (38.1 %) 7 (16.7 %)
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No significant association was found between treat-
ment and MTHFR C677T polymorphism, but CT geno-
type was more frequent in patient, who use of the mixed 
antidepressant. This choice by doctors can be explained 
by the responses of depressive patients to the treat-
ment. In literature, Shen et al. [24] report in Chinese Han 
population that MTHFR C677T interact with COMT 
Val158Met, to increase Major depressive disorder but 
without influencing on treatment responses. Bousman 
et al. [49] show the absence of remission for patients who 
have CC genotype after treatment. This contradiction 
may be explained by the influence of environmental fac-
tors, genetic variant interaction and socio-demographical 
interaction.
Conclusions
This paper is the first study to prove that in Tunisian 
population of center region exist positive associations 
between depressive disorder and the C677T polymor-
phism and especially with CT and TT genotype. In our 
population, the more a person becomes aged, the more 
he is risked to have this pathology. In our case of study, 
we found that TT genotype is associated with depression 
and this association is more frequent in women, more 
than in men. In another hand, we considered that CT 
genotype is a protector from depression; however, major 
frequency of alcohol consumers, drugs abuse and smok-
ing patients has a CT genotype, so it is no longer a pro-
tector because it seems that it is associated with addictive 
behavior in depressed people.
So this genotype may be used as a genetic marker to 
identify a patient with a higher risk of development of 
depressive disorder for better therapeutic management 
and prevent disease installation through treatment, psy-
chological support and nutrition. But this study must be 
confirmed with other works with larger population.
More genetic and biochemical investigations are rec-
ommended to have a better comprehension for this 
disease. A detection particular with combination of poly-
morphism of different genes may confer a better explora-
tion of earlier onset or presence of the different forms of 
pathology. Further studies of genetic polymorphism and 
a possible correlation with pathology, may lead to dis-
cover a novel marker to identify a patient with a higher 
risk of development of depressive disorder.
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SIRS selective inhibitors of serotonin reuptake, TCA tricyclic antidepressant, Atypical venlafaxine, milnacipran
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